—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Genmab AS (GMAB) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for GMAB, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.59 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How GMAB has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.59 — tends to move with bonds for every 1% move in TLT (20+ year Treasuries), Genmab AS moved 0.59% on average · correlation 0.16 · higher than 60% of US names
  • Beta, last 3 months 0.63 about the same as over the year
  • On the 10 worst bond days −1.13% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.23% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GMAB on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Genmab AS

GMAB in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Genmab develops antibody-based medicines for cancer and other diseases, working from Copenhagen with additional roots in Denmark's biotech sector. It markets treatments such as Tivdak and Epkinly for blood and cervical cancers, and shares several approved drugs, including Darzalex and Tecvayli, through partnerships with larger pharmaceutical firms. Its pipeline includes further antibody candidates aimed at solid tumours, leukaemia and other conditions, still in various stages of development.
Where it sits in the stack
Genmab carries no seat in our index; it belongs to the Healthcare sector sleeve of the diary's US universe, where its business rests on royalties and shared revenue from approved antibody therapies rather than on any single owned product line.
Who it is priced against
Closelooknet's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names AstraZeneca as a comparable oncology-antibody developer.
Why Closelooknet tracks it
It carries a Closelooknet score with momentum as its strongest module and valuation as its weakest; it holds no index seat and has not yet appeared in the diary's quoted editions.
What the diary watches
Whether new approvals or expanded partner deals convert its pipeline into steadier royalty income, since much of its revenue still depends on collaborations with other drugmakers.

Genmab AS (GMAB) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Guggenheim, 2026-10-05

The Street on this name

Analyst actions and the latest print for GMAB from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Guggenheim — target 54 Target set to $54 (+55.4% to spot) 2026-10-05

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Genmab AS (GMAB)?

Genmab AS trades as GMAB on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is GMAB in a Closelooknet index?

Not currently — Genmab AS is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does GMAB trade against its moving averages?

Uptrend stack intact: Trades +14.4% vs the 50-day and +27.3% vs the 200-day average, 5.9% below the 52-week high and +60% off the 52-week low; a golden cross printed 29 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Genmab AS compare with its peers?

Against its peer group (Biotechnology · US), Genmab AS (GMAB) sits 5.9% below its 52-week high, 14.4% above its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to GMAB in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Genmab AS trade when bond yields rise?

Over the past year Genmab AS had a beta of 0.59 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 60% of US names. On the 10 sessions in which long bonds fell most it moved −1.13% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Genmab AS do?

Genmab develops antibody-based medicines for cancer and other diseases, working from Copenhagen with additional roots in Denmark's biotech sector. It markets treatments such as Tivdak and Epkinly for blood and cervical cancers, and shares several approved drugs, including Darzalex and Tecvayli, through partnerships with larger pharmaceutical firms. Its pipeline includes further antibody candidates aimed at solid tumours, leukaemia and other conditions, still in various stages of development. Closelooknet's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names AstraZeneca as a comparable oncology-antibody developer.

Where does Genmab AS sit in the AI build-out?

Genmab carries no seat in our index; it belongs to the Healthcare sector sleeve of the diary's US universe, where its business rests on royalties and shared revenue from approved antibody therapies rather than on any single owned product line. It carries a Closelooknet score with momentum as its strongest module and valuation as its weakest; it holds no index seat and has not yet appeared in the diary's quoted editions.

What has Wall Street done on Genmab AS recently?

The most recent analyst action on Genmab AS on the Closelooknet wire is a price target by Guggenheim on 2026-10-05 (target 54). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for GMAB, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.